Compare ACADIA Pharmaceuticals Inc. (ACAD) vs MasterCard Inc (MA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs MasterCard Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.88 (market cap $4.49B), while MasterCard Inc trades at $520.08 (market cap $469.73B). The key difference: MasterCard Inc is far larger — about 104.6× ACADIA Pharmaceuticals Inc.'s market cap, and MasterCard Inc pays a 0.65% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | MA | |
|---|---|---|
Market Cap | $4.49B | $469.73B |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $598.96 |
52-Week Low | $20.06 | $471.55 |
Enterprise Value | $3.69B | $480.47B |
Volume | — | 4,635,698 |
Dividend Yield | — | 0.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Mastercard (MA) trades at $519.68, down 2.52% on the day, but maintains a strong fundamental profile with consistent earnings beats and robust profitability. The stock shows a bullish technical trend, supported by positive moving averages, while recent news highlights institutional accumulation and strategic initiatives in AI and financial inclusion. Revenue growth remains steady, climbing to $32.79B in 2025, with a net income margin of 45.88%.
Outlook is positive given analyst consensus with a $637.67 price target and 79% buy ratings. Key opportunities include digital payment expansion and high margins, but risks involve competitive disruption from stablecoins and elevated valuation multiples. The stock offers growth potential tempered by market volatility and technological shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →
